Your search for non small cell lung cancer returned 6 results

Higher major pathological response seen for patients with resectable NSCLC treated with combo versus durvalumab alone.

New research suggests that mRNA COVID-19 vaccines can elevate PD-L1 expression levels in patients with advanced non-small cell lung cancer.

Starting treatment for advanced NSCLC before receiving genomic test results compromises patient outcomes, a study suggests.

Gavreto is an oral tyrosine kinase inhibitor.

Proton pump inhibitor use is associated with shorter survival among patients with non-small cell lung cancer treated with pembrolizumab monotherapy.

Phase 3 trial results support atezolizumab as a potential first-line treatment option for patients with advanced non-small cell lung cancer.